Navigation Links
Hallucinogen appears safe, may improve mood among patients with advanced-stage cancer and anxiety
Date:9/6/2010

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

"In recent years, there has been a growing awareness that the psychological, spiritual and existential crises often encountered by patients with cancer and their families need to be addressed more vigorously," the authors write as background information in the article. "From the late 1950s to the early 1970s, research was carried out exploring the use of hallucinogens to treat the existential anxiety, despair and isolation often associated with advanced-stage cancer. Those studies described critically ill individuals undergoing psychospiritual epiphanies, often with powerful and sustained improvement in mood and anxiety as well as diminished need for narcotic pain medication."

Despite initial promising results, no follow-up research had been conducted; however, the medical value of hallucinogens is now being re-examined in psychiatric settings, the authors note. Charles S. Grob, M.D., of Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, explored the safety and efficacy of psilocybina hallucinogen with some psychological effects similar to lysergic acid diethylamide (LSD)among 12 adults with advanced-stage cancer and anxiety.

Participants served as their own controls; in two six-hour treatment sessions several weeks apart, they were given clear capsules either of active psilocybin (in a dose of 0.2 milligrams per kilogram) or a placebo (niacin, 250 milligrams) in random order. Physiological responses such as blood pressure, heart rate and temperature were measured before and after, and psychological measures including assessments of depression, mood and anxiety were administered before and at the end of the session, one day and two weeks after the session and at monthly intervals for the following six months.

"Safe physiological and psychological responses were documented during treatment sessions," the authors write. "We also observed no adverse psychological effects from the treatment. All subjects tolerated the treatment sessions well, with no indication of severe anxiety or a 'bad trip.'" In addition, anxiety scores improved at one and three months after treatment and a depression inventory revealed an improvement of mood that began two weeks after treatment and reached significance at six months.

"This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety," the authors conclude. "Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field."


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. FDA Panel Appears Skeptical Over Key Avandia Data
2. Plasma protein appears to be associated with development and severity of Alzheimers disease
3. Celebrex Appears Easier on Stomach for Arthritis Patients
4. NAMI Medical Director Honored with APA Patient Advocacy Award; Appears in CNN Health and Huffington Post Columns
5. Taking Flu Drugs While Pregnant Appears to Be Safe: Study
6. Hospitalization Appears to Help Personality Disorder Patients
7. How health care is paid for appears to impact outcome
8. Protein Appears Key to Intestinal Balance
9. Eggs Being Produced by Recall Farms Safe, if Pasteurized, Experts Say
10. Drug-eluting stents confirmed safe, effective for long-term use
11. Declare Your Skin-dependence this Holiday with Patriotic, Playful Products from TruKid, the Award-Winning Line of Safe, Natural Products for Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... spark a conversation on the current obstacles facing infection prevention and offer strategies ... deaths caused by these infections. , The print component of “Fighting Infection” ...
(Date:3/24/2017)... Dallas, Texas (PRWEB) , ... March 24, 2017 , ... ... Budget Office score is invalid because it does not obey the rules Congress has ... million full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a ...
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in Southlake, ... leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” ... designed to teach how to maximize their sales efforts, as well as how ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 ... market of deep learning solutions within the healthcare domain. Primarily driven ... a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... -- GenomeDx Biosciences today announced that six abstracts featuring Decipher ... Classifier tests will be presented at the 32 nd ... March 24 to 28, 2017 in London, ... Europe,s largest urological event showcasing the ... The abstract titled "Muscle invasive bladder cancer: ...
Breaking Medicine Technology: